Achievement and duration of 12-week and 24-week erythroid responses. (A) Achievement of 12-week erythroid response; (B) total (cumulative) duration of 12-week erythroid response by data cutoff date; (C) achievement of 24-week erythroid response; (D) total (cumulative) duration of 24-week erythroid response by data cutoff date. Median (range) treatment durations at the primary data cutoff, longer-term data cutoff, and study completion date were 99.7 (15.0-132.1) vs 61.1 (3.0-121.9), 150.1 (15.0-185.4) vs 61.1 (3.0-138.0), and 202.8 (15.0-242.3) vs 61.1 (3.0-138.0) weeks, respectively, for luspatercept vs placebo.